www.remynd.com Open in urlscan Pro
148.251.123.139  Public Scan

Form analysis
1 forms found in the DOM

POST /

<form class="webform-client-form webform-client-form-169 form" action="/" method="post" id="webform-client-form-169" accept-charset="UTF-8">
  <div>
    <div class="webform-component-fieldset input-group input-group-lg c-square webform-component--wrapper form-wrapper"><input required="required" class="email c-input form-control c-square c-theme form-control required" placeholder="Your Email Here"
        id="edit-submitted-wrapper-email-clean" name="submitted[wrapper][email_clean]" value="" size="60"><span class="input-group-btn">
        <button class="btn c-theme-btn c-theme-border c-btn-square c-btn-uppercase c-font-16" type="button">Subscribe</button>
      </span></div><input type="hidden" name="details[sid]">
    <input type="hidden" name="details[page_num]" value="1">
    <input type="hidden" name="details[page_count]" value="1">
    <input type="hidden" name="details[finished]" value="0">
    <input type="hidden" name="form_build_id" value="form-XwEygTD0TY3Uas683yRmSYfOxfr_LuWTXB0JKPcZ82I">
    <input type="hidden" name="form_id" value="webform_client_form_169">
    <div class="form-actions"><input class="webform-submit button-primary btn-medium btn btn-mod hidden form-submit btn c-btn c-btn-square c-theme-btn c-font-bold c-font-uppercase c-font-white" type="submit" name="op" value="<none>"></div>
  </div>
</form>

Text Content

Skip to main content
 * Home
 * Platform & products
   * * Lead Alzheimer program ReS19-T
     * Huntington program ReS18-H
     * Orphan programs
 * Services
   * * APP-London model
     * APPxPS1 model
     * Tau[P301L] model
     * Tau[P301S] model
     * APP[V717I]xTau[P301L] model
     * APP[V717I]xTau[P301S] model
     * Seed and spread Tauopathy model
 * About us
   * * People
     * News
       * * reMYND’s novel Alzheimer program reports excellent brain exposure and
           safety profile in Phase 1; transitioning into Phase 2a
         * reMYND’s ReS19-T program, managing calcium homeostasis for
           Alzheimer’s, has moved to MAD phase after demonstrating strong safety
           in SAD phase
         * reMYND identifies novel target and small molecules with potential to
           halt and reverse disease progression in Huntington’s disease through
           oral administration
         * reMYND extends Series B funding to EUR 24 million
         * reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
         * reMYND appoints Dr. Lode Debrabandere as Chief Business Officer
         * reMYND announces Clinical Advisory Board to support development of
           Alzheimer’s programme
         * reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP)
           begin collaboration on epilepsy program
         * Interreg. project "Memories" update
         * Interreg. project "Memories" holds 2nd annual symposium & new
           newsletter is available
         * Approved project ‘Memories’ (‘Herinneringen’ in Dutch): early
           diagnostics of Alzheimer’s disease (AD)
     * Partners
 * Jobs
   * * Research Associate
     * Quality Associate
 * Contact


RESTORING FUNCTION
IN ALZHEIMER’S, HUNTINGTON'S AND OTHER DISEASES CAUSED BY CELLULAR DYSFUNCTION


PLATFORM & PRODUCTS

reMYND is developing first-in-class treatments to restore function in patients
with Alzheimer's, Huntington's, as well as other diseases caused by cellular
dysfunction, backed by a proprietary drug discovery platform:


LEAD ALZHEIMER'S PROGRAM

Providing an immediate cognitive improvement by restoring synaptic function and
reducing as well aBeta as Tau pathology over time


LEAD HUNTINGTON'S PROGRAM

Restoring cortico-striatal transmission and regenerating the brain


DISCOVERY PROGRAMS

Discovery programs with in vivo proof-of-concept in Epilepsy. Proof-of-concept
in ALS is ongoing.

Discover our platform & products


SERVICES

Our Contract Research Organization (CRO) helps our clients assess the effects of
their experimental Alzheimer and other neurodegenerative disease treatments in
our proprietary mouse models.

We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US,
Europe and Japan. We have provided pivotal in-vivo proof-of-concept data for
several candidate drugs currently in clinical development, and work actively
together with Dr. Sugimoto, the inventor of Aricept. We have helped our clients
to be the first to demonstrate the synergistic effect of a BACE inhibitor and an
aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on
brain Abeta, …

Learn more about our services


ABOUT US

reMYND is a clinical stage company developing treatments for Alzheimer’s,
Huntington's, epilepsy and other diseases caused by cellular dysfunction. It is
backed by a proprietary drug discovery platform, which enables the
identification of novel mechanisms-of-action, targets and first-in-class small
molecules. reMYND’s most advanced program is ReS19-T, an investigational
compound for the treatment of Alzheimer’s, ready to start Phase 2a.

In addition, reMYND has a dedicated Contract Research Organization (CRO), which
focuses on CNS disorders. The team helps clients to assess the pharmacokinetics,
pharmacodynamics and efficacy of their experimental treatments in reMYND’s
proprietary animal models. The CRO has a global client base, including the US,
Europe and Japan.

reMYND has been substantially supported by grants from VLAIO, the European Union
and The Michael J Fox Foundation.

Meet our team Read our news


 * Home
 * Platform & products
 * Services
 * About us
 * Jobs
 * Contact


PARTNERS





CRO NEWS FLASHES


SUBSCRIBE INLINE

Subscribe



CONTACT

reMYND, Bio-Incubator (Wetenschapspark)
Gaston Geenslaan 1
BE-3001 Leuven (Heverlee)
Belgium

RPR Leuven, 0476.910.101
BTW/VAT: BE0476.910.101

T +32 16 75 14 20
F +32 16 75 14 21
info@remynd.com




Terms & conditions